Combination fertility agent (insulin sensitizer + ovulation inducer + gonadotropin)

This page covers all Combination fertility agent (insulin sensitizer + ovulation inducer + gonadotropin) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Progesterone receptor, estrogen receptor, inositol signaling pathway, Mitochondrial pyruvate carrier (MPC).

Targets

Progesterone receptor, estrogen receptor, inositol signaling pathway · Mitochondrial pyruvate carrier (MPC)

Marketed (2)

• Metformin / clomid / hCG · The Egyptian IVF-ET Center · Reproductive Medicine / Fertility
  This combination uses metformin to improve insulin sensitivity, clomiphene citrate to stimulate ovulation, and human chorionic gonadotropin (hCG) to support the luteal phase and early pregnancy in assisted reproductive technology.
• Drospirenone Ethinyl estradiol Myo-inositol · AGUNCO Obstetrics and Gynecology Centre · Gynecology / Reproductive Health
  This combination oral contraceptive suppresses ovulation through progestin and estrogen activity while myo-inositol may improve insulin sensitivity and metabolic parameters.

Phase 3 pipeline (1)

• MSDC-0602K · Cirius Therapeutics, Inc. · Metabolic / Endocrinology
  MSDC-0602K is a thiazolidinedione-class insulin sensitizer that activates mitochondrial pyruvate carrier (MPC) to improve insulin sensitivity and glucose metabolism.

Phase 2 pipeline (1)

• D-chiro-inositol · Biosearch S.A. · Metabolic disorders
  D-chiro-inositol is involved in insulin signaling and glucose metabolism.

Patent intelligence

• insulin sensitizer patent landscape — aggregated cliff calendar, attackable patents, originator estates